From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 1991
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 8.19
Pain Relevance 2.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (CYP27A1) small molecule metabolic process (CYP27A1)
Anatomy Link Frequency
urine 2
articular 1
osteoblasts 1
Cleavage 1
knee 1
CYP27A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Osteoarthritis 404 98.98 Very High Very High Very High
rheumatoid arthritis 68 98.92 Very High Very High Very High
withdrawal 2 93.12 High High
Bile 2 92.04 High High
Adalimumab 1 89.92 High High
Infliximab 6 89.36 High High
cytokine 31 86.36 High High
Central nervous system 3 82.72 Quite High
Spinal cord 1 80.64 Quite High
anesthesia 1 79.36 Quite High
Disease Link Frequency Relevance Heat
Osteoporosis 167 100.00 Very High Very High Very High
Hypercalcemia 115 100.00 Very High Very High Very High
Osteoarthritis 273 98.98 Very High Very High Very High
Rheumatoid Arthritis 87 98.92 Very High Very High Very High
Frailty 109 95.64 Very High Very High Very High
Knee Osteoarthritis 48 94.64 High High
Van Bogaert's Disease 6 94.36 High High
Disease 94 92.60 High High
Osteophyte 15 91.76 High High
Cirrhosis 10 87.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We have localized the CYP27 gene to the q33-qter interval of human chromosome 2, and to mouse chromosome 1, in agreement with the autosomal recessive inheritance pattern of CTX.
Localization (localized) of CYP27 gene associated with van bogaert's disease
1) Confidence 0.80 Published 1991 Journal J. Biol. Chem. Section Abstract Doc Link 2019602 Disease Relevance 0.97 Pain Relevance 0.28
Cleavage of type I collagen results in release of C-terminal telopeptide of collagen type I (CTX-I) [20,21], which has been used extensively as a surrogate measure of bone resorption for in vitro, preclinical and clinical studies [20,22].
Localization (release) of CTX-I in Cleavage associated with hypercalcemia
2) Confidence 0.61 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2902412 Disease Relevance 1.04 Pain Relevance 0.40
These data come from the population-based Chingford study, conducted in 216 women in whom urine from three time points was assayed for urinary collagen cross-link excretion (urine C-telopeptide of type I collagen (CTx) and NTx).
Localization (excretion) of CTx in urine
3) Confidence 0.50 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575616 Disease Relevance 1.03 Pain Relevance 0.37
A reduced rate of bone turnover, as evidenced by low serum bone markers levels, such as serum beta-CTx, may predispose to ONJ, and therefore assaying these levels may be helpful in identifying patients susceptible to BON.91 On the other hand, cases of BON have been reported in patients with normal CTx levels,92 and the presently available data do not support the use of serum CTx to assess the risk of BON.61
Localization (use) of serum CTx
4) Confidence 0.39 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998805 Disease Relevance 0.10 Pain Relevance 0.05
We found that CTX-I had decreased significantly in the HRT group, by 62% and 53% at 1 and 2 years, respectively.
Localization (decreased) of CTX-I
5) Confidence 0.37 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0.36 Pain Relevance 0.13
The association of urinary CTX-II and progression of knee OA could be explained by the studies suggesting that CTX-II is not only released from the surface of the cartilage, but also from the bone to cartilage interface region within the calcified region.24,25 The rapid reduction in urinary levels of CTX-II might be attributable to decreases in subchondral bone turnover and articular and/or calcified cartilage degradation.11
Localization (released) of CTX-II in articular associated with osteoarthritis
6) Confidence 0.32 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.54 Pain Relevance 0.25
40%, and serum C-telopeptide of type 1 collagen (CTx) ?
Localization (telopeptide) of CTx
7) Confidence 0.28 Published 2006 Journal Clinical Interventions in Aging Section Body Doc Link PMC2699644 Disease Relevance 0.12 Pain Relevance 0
Thus CTX-1 decreased rapidly within the first three months, which was more pronounced in the P-group.
Localization (decreased) of CTX-1
8) Confidence 0.19 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656227 Disease Relevance 1.02 Pain Relevance 0.18
On the contrary tamoxifen induced a marked decrease in both bone resorption markers (CTX: ?
Localization (decrease) of CTX associated with hypercalcemia
9) Confidence 0.17 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682397 Disease Relevance 0.37 Pain Relevance 0.05
When type II collagen is broken down, collagen fragments (CTX II) are released into the circulation and excreted in urine [59].
Localization (released) of CTX in urine
10) Confidence 0.15 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1860072 Disease Relevance 0.46 Pain Relevance 0.11
Monthly ibandronate also showed dose-dependent decreases in serum CTX, a marker of bone resorption.
Localization (decreases) of serum CTX associated with hypercalcemia
11) Confidence 0.12 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661644 Disease Relevance 0.10 Pain Relevance 0
Osteocalcin is a noncollagenous protein secreted by osteoblasts and is widely accepted as a marker for osteoblastic activity [34] and bone formation [35], whereas serum CTX, as a collagen-degradation product is a marker of bone resorption [36].
Localization (secreted) of serum CTX in osteoblasts associated with hypercalcemia and osteoporosis
12) Confidence 0.09 Published 2005 Journal BMC Gastroenterol Section Body Doc Link PMC1242225 Disease Relevance 0.96 Pain Relevance 0.08
Intravenous ibandronate concomitantly and dose-dependently suppressed markers of bone turnover in comparison with placebo. sCTX and urinary CTX/creatinine were reduced by 42% and 50% after 12 months for patients receiving 2 mg ibandronate every 3 months compared with 9% and 7% for patients receiving placebo plus calcium, respectively.
Localization (creatinine) of CTX
13) Confidence 0.03 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684081 Disease Relevance 0.39 Pain Relevance 0
In a prospective study comparing patients with knee OA flare treated with rofecoxib versus placebo, uCTX-II levels were 18% lower (p = 0.0003) in the treatment group compared to the placebo group, although the possibility cannot be ruled out that the drug decreased renal excretion of CTX-II (Gineyts E, 2004).
Localization (excretion) of CTX-II in knee associated with osteoarthritis
14) Confidence 0.01 Published 2006 Journal Biomark Insights Section Body Doc Link PMC2716783 Disease Relevance 0.72 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools